Literature DB >> 21308543

Mycoplasma pneumoniae: Innocent Bystander or a True Cause of Central Nervous System Disease?

Ari Bitnun1, Susan E Richardson.   

Abstract

The consistency with which Mycoplasma pneumoniae has been implicated as a cause of encephalitis, and the increased incidence of central nervous system (CNS) disease observed during M. pneumoniae respiratory outbreaks, support the role of M. pneumoniae as a CNS pathogen. Three pathophysiologic mechanisms have been proposed: direct infection, autoimmunity, and vascular occlusion. Recent evidence demonstrating the organism's ability to survive intracellularly, presence of its DNA in the serum of individuals with acute encephalitis, case reports in which the organism is detected in brain parenchyma or cerebrospinal fluid (CSF), and animal data demonstrating CNS invasion by several Mycoplasma species support the contention that M. pneumoniae is capable of direct infection of the CNS. Because of limitations of current serologic assays and difficulty in interpreting the significance of positive polymerase chain reaction results in regard to acuity of infection and viability of the organism, the diagnosis of M. pneumoniae-associated CNS disease should be based on a combination of positive tests and exclusion of alternative diagnoses.

Entities:  

Year:  2010        PMID: 21308543     DOI: 10.1007/s11908-010-0105-4

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  62 in total

1.  Isolation and characterization of Mycoplasma pneumoniae from cerebrospinal fluid of a patient with pneumonia and meningoencephalitis.

Authors:  I Kasahara; Y Otsubo; T Yanase; H Oshima; H Ichimaru; M Nakamura
Journal:  J Infect Dis       Date:  1985-10       Impact factor: 5.226

2.  A dipalmitoylated lipoprotein from Mycoplasma pneumoniae activates NF-kappa B through TLR1, TLR2, and TLR6.

Authors:  Takashi Shimizu; Yutaka Kida; Koichi Kuwano
Journal:  J Immunol       Date:  2005-10-01       Impact factor: 5.422

3.  Fatal encephalitis caused by Mycoplasma pneumoniae in a 9-year-old girl.

Authors:  J H Tjhie; E M van de Putte; K Haasnoot; A J van den Brule; C M Vandenbroucke-Grauls
Journal:  Scand J Infect Dis       Date:  1997

Review 4.  Pathogenesis of neurologic manifestations of Mycoplasma pneumoniae infection.

Authors:  Mitsuo Narita
Journal:  Pediatr Neurol       Date:  2009-09       Impact factor: 3.372

5.  Acute disseminated encephalomyelitis (ADEM) due to Mycoplasma pneumoniae infection in an adolescent.

Authors:  K Riedel; V A Kempf; A Bechtold; M Klimmer
Journal:  Infection       Date:  2001-08       Impact factor: 3.553

6.  Post-infectious encephalitis with anti-galactocerebroside antibody subsequent to Mycoplasma pneumoniae infection.

Authors:  M Nishimura; T Saida; S Kuroki; T Kawabata; H Obayashi; K Saida; T Uchiyama
Journal:  J Neurol Sci       Date:  1996-09-01       Impact factor: 3.181

7.  Neurological symptoms in patients whose cerebrospinal fluid is culture- and/or polymerase chain reaction-positive for Mycoplasma pneumoniae.

Authors:  M Socan; I Ravnik; D Bencina; P Dovc; B Zakotnik; J Jazbec
Journal:  Clin Infect Dis       Date:  2000-12-20       Impact factor: 9.079

Review 8.  Mycoplasma pneumoniae ecephalitis.

Authors:  Ari Bitnun; Elizabeth Ford-Jones; Susan Blaser; Susan Richardson
Journal:  Semin Pediatr Infect Dis       Date:  2003-04

Review 9.  Cutaneous vasculitis associated with Mycoplasma pneumoniae infection: case report and literature review.

Authors:  Filippo Greco; Anna Sorge; Vincenzo Salvo; Giovanni Sorge
Journal:  Clin Pediatr (Phila)       Date:  2007-06       Impact factor: 1.168

10.  Mycoplasma pulmonis infection in the brains of rodents.

Authors:  A Hill
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

View more
  9 in total

1.  Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium.

Authors:  A Venkatesan; A R Tunkel; K C Bloch; A S Lauring; J Sejvar; A Bitnun; J-P Stahl; A Mailles; M Drebot; C E Rupprecht; J Yoder; J R Cope; M R Wilson; R J Whitley; J Sullivan; J Granerod; C Jones; K Eastwood; K N Ward; D N Durrheim; M V Solbrig; L Guo-Dong; C A Glaser
Journal:  Clin Infect Dis       Date:  2013-07-15       Impact factor: 9.079

2.  Childhood encephalitis in Canada in 2015.

Authors:  Ari Bitnun; Susan E Richardson
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 Mar-Apr       Impact factor: 2.471

Review 3.  Classification of Extrapulmonary Manifestations Due to Mycoplasma pneumoniae Infection on the Basis of Possible Pathogenesis.

Authors:  Mitsuo Narita
Journal:  Front Microbiol       Date:  2016-01-28       Impact factor: 5.640

4.  Evaluation of variation in coagulation among children with Mycoplasma pneumoniae pneumonia: a case-control study.

Authors:  Tianhua Li; Haiying Yu; Weina Hou; Zhiyong Li; Chunfang Han; Lihong Wang
Journal:  J Int Med Res       Date:  2017-06-23       Impact factor: 1.671

5.  Mycoplasma pneumoniaeassociated transverse myelitis presenting as asymmetric flaccid paralysis.

Authors:  Shafee Salloum; Ajay Goenka; Elizabeth Ey
Journal:  Clin Pract       Date:  2019-09-12

6.  Role of infectious agents in the carcinogenesis of brain and head and neck cancers.

Authors:  Kenneth Alibek; Ainur Kakpenova; Yeldar Baiken
Journal:  Infect Agent Cancer       Date:  2013-02-02       Impact factor: 2.965

7.  Complete occlusion of the right middle cerebral artery associated with Mycoplasma pneumoniae pneumonia.

Authors:  Ben Kang; Dong Hyun Kim; Young Jin Hong; Byong Kwan Son; Myung Kwan Lim; Yon Ho Choe; Young Se Kwon
Journal:  Korean J Pediatr       Date:  2016-03-31

8.  Mycoplasma pneumoniae, a trigger for Weston Hurst syndrome.

Authors:  Rick Magun; Chris P Verschoor; Dawn M E Bowdish; John Provias
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-01-21

Review 9.  Acute encephalitis.

Authors:  Dennis W Simon; Yong Sing Da Silva; Giulio Zuccoli; Robert S B Clark
Journal:  Crit Care Clin       Date:  2013-02-11       Impact factor: 3.598

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.